Atossa Genetics (NASDAQ:ATOS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Atossa Genetics (NASDAQ:ATOS) had its price target hoisted by stock analysts at HC Wainwright to $25.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 429.66% from the company’s previous close. HC Wainwright also issued estimates for Atossa Genetics’ FY2030 earnings at ($0.15) EPS.

A number of other research firms have also commented on ATOS. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Ascendiant Capital Markets upped their price target on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $68.33.

Atossa Genetics Stock Up 0.2%

Shares of Atossa Genetics stock opened at $4.72 on Thursday. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The company has a market cap of $40.64 million, a PE ratio of -1.31 and a beta of 1.42. The business has a 50 day moving average of $5.71 and a 200 day moving average of $9.93.

Institutional Trading of Atossa Genetics

Several large investors have recently bought and sold shares of ATOS. Hudson Bay Capital Management LP purchased a new stake in shares of Atossa Genetics in the 2nd quarter valued at $26,000. Gallagher Capital Advisors LLC purchased a new position in Atossa Genetics during the third quarter valued at approximately $27,000. JPMorgan Chase & Co. raised its position in Atossa Genetics by 1,294.2% during the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares in the last quarter. &PARTNERS purchased a new stake in Atossa Genetics during the fourth quarter worth $25,000. Finally, Bank of America Corp DE boosted its holdings in Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after buying an additional 35,629 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.